Novel psychoactive substances (NPS) continue to signify a risk to public overall health and basic safety. The quantity of new prescription drugs in the most recent emergent synthetic opioid course—the 2-benzylbenzimidazole analogs—also known as the nitazenes—has begun to dominate the current new artificial opioid (NSO) subclass of NPS.The gre